Truist lifts Regeneron price target to $780
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Truist Financial raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $780 from $772, keeping a buy rating. The move follows a broadly positive analyst backdrop, with JPMorgan and Guggenheim also lifting targets recently. Regeneron beat earnings expectations for its latest quarter, reporting EPS of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context